Nuvo Pharmaceuticals Announces Fourth Quarter 2019 Results Release Date and Conference Call Details

MISSISSAUGA, ON, Feb. 11, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its fourth quarter 2019 financial results before markets open on Tuesday, February 25, 2020.

The Company will subsequently hold a conference call that same day, Tuesday, February 25, 2020 at 8:30 a.m. ET, hosted by Jesse Ledger, Nuvo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

The audio webcast can be accessed at:

https://event.on24.com/wcc/r/2157012/58177B40029B0BCD961B0D0EFB9562A9

An archived replay of the webcast will be available by clicking the link above.

About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX: NRIFF) is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Nuvo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the U.S. Food and Drug Administration (FDA), Health Canada and E.U. approved manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the FDA. For additional information, please visit www.nuvopharmaceuticals.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-announces-fourth-quarter-2019-results-release-date-and-conference-call-details-301002422.html

SOURCE Nuvo Pharmaceuticals Inc.